| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1096-8628(20000814)93:4<320::AID-AJMG12>3.0.CO;2-R |
| P698 | PubMed publication ID | 10946360 |
| P50 | author | Douglas A Marchuk | Q93131481 |
| P2093 | author name string | Nelson L | |
| Ward KJ | |||
| Marchuk DA | |||
| Miller FJ | |||
| McDonald JE | |||
| Hallam SE | |||
| P2860 | cites work | Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy | Q41252993 |
| Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. | Q50605218 | ||
| Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: Doppler sonographic screening in a large family. | Q50956254 | ||
| Pulmonary arteriovenous malformations: how do we diagnose them and why is it important to do so? | Q52423838 | ||
| Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 | Q24317667 | ||
| The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2 | Q24678806 | ||
| Hereditary haemorrhagic telangiectasia: a clinical analysis | Q33594300 | ||
| Genetic heterogeneity in hereditary haemorrhagic telangiectasia | Q33596273 | ||
| Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype | Q33596279 | ||
| Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity | Q33596285 | ||
| Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? | Q33683412 | ||
| Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). | Q33897059 | ||
| Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. | Q34381015 | ||
| A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. | Q34389653 | ||
| Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia | Q35248963 | ||
| Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients | Q40819926 | ||
| P433 | issue | 4 | |
| P921 | main subject | hereditary hemorrhagic telangiectasia | Q776881 |
| P304 | page(s) | 320-327 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | American Journal of Medical Genetics Part A | Q15755121 |
| P1476 | title | Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred | |
| P478 | volume | 93 |
| Q34999903 | A case report of a patient with hereditary hemorrhagic telangiectasia treated successively with thalidomide and bevacizumab |
| Q36281641 | A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study |
| Q33976779 | A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia |
| Q28588420 | ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2 |
| Q38662338 | Arteriovenous malformations in hereditary haemorrhagic telangiectasia: looking beyond ALK1-NOTCH interactions. |
| Q57469996 | Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of Portopulmonary Hypertension |
| Q44407006 | Disease-associated mutations in conserved residues of ALK-1 kinase domain |
| Q92978893 | Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations |
| Q35554323 | Fishing for novel angiogenic therapies |
| Q31092753 | Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network |
| Q36294968 | Hereditary Haemorrhagic Telangiectasia Cerebrospinal Localization in Adults and Children. Review of 39 cases |
| Q35059330 | Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. |
| Q35443250 | Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations |
| Q35842042 | Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians |
| Q40218859 | How to identify pediatric cerebral and pulmonary arteriovenous malformation earlier: non-hereditary hemorrhagic telangiectasia case |
| Q46316673 | Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia |
| Q28506951 | Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor |
| Q24302138 | Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia |
| Q44801721 | Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France |
| Q36246414 | Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years |
| Q34388065 | Optimal management of hereditary hemorrhagic telangiectasia |
| Q35018094 | Plumbing the mysteries of vascular development using the zebrafish |
| Q30491276 | Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia |
| Q73424850 | SIR 2003 film panel case 3: hemorrhagic hereditary telangectasia with median arcuate ligament compression |
| Q37346515 | The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance |
| Q36023813 | The biological "scrabble" of pulmonary arteriovenous malformations: considerations in the setting of cavopulmonary surgery |
| Q34544980 | The pathobiology of vascular malformations: insights from human and model organism genetics |
| Q35443190 | Visceral manifestations in hereditary haemorrhagic telangiectasia type 2 |
| Q83044269 | [64-year old patient with tachycardia and signs of heart failure] |
| Q84394415 | [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia] |
Search more.